The World Federation of Hemophilia strongly recommends that patients with a severe hemophilia phenotype have to be on prophylaxis sufficient to prevent articular and musculoskeletal bleeds.[5] The plasma half-life of standard-acting (SHL) FVIII products is in the range of 8 to 12 hours, being approximately 12 hours on average. Here, F8 is linked to hemophilia.